Acute myocardial mechanical responses to colloid and crystalloid volume loading: A randomized double-blind crossover study.

Br J Clin PharmacolMay 25, 2026 (epub)
Clinical ResearchCardiologyOpen access

Nidhal Bouchahda, Fabian Scheipl, Haithem Hbid et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized double-blind crossover trial investigated myocardial mechanical responses to colloid (Gelafundin 4%) versus crystalloid (0.9% sodium chloride) volume loading in 20 healthy volunteers. The study found that left ventricular global longitudinal strain (GLS) differed significantly between the two fluids, with a maximum difference of -1% favoring colloids, indicating distinct myocardial responses to volume resuscitation.

Key findings

  • Left ventricular global longitudinal strain (GLS) differed significantly between fluids, with a maximum difference of -1% favoring colloids.
  • Right ventricular strain showed significant differences primarily during diastole, with a maximum difference of +2%.
  • Left ventricular torsion increased significantly with colloid, showing a maximum difference of +3%.
  • Left atrial strain exhibited the largest differences at both infusion volumes, with a maximum difference of +6%.

Why it matters

Understanding the differential myocardial responses to colloid and crystalloid resuscitation can inform clinical decisions regarding fluid management in patients requiring volume resuscitation, potentially impacting outcomes in critical care settings.

Source

Published in Br J Clin Pharmacol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.